Sudha Seshadri, M.D.

 

Sudha Seshadri, M.D.
Founding Director
Glenn Biggs Institute for Alzheimer’s & Neurodegenerative Diseases
The University of Texas Health San Antonio


Presentation: Are We on the Horizon of a “Cure” for Alzheimer’s Disease?


Dr. Sudha Seshadri completed her M.B.B.S. from the Christian Medical College, Madras University, and her M.D. in internal medicine and D.M. in neurology from the All India Institute of Medical Sciences, New Delhi, India. Additionally, she has completed a residency in neurology at the Boston University School of Medicine and a fellowship in the neurobiology of Aging and Alzheimer Disease at the University of Massachusetts Medical Center. She has previously worked as assistant professor of neurology at the All India Institute of Medical Sciences and professor of neurology and attending neurologist at the Boston University School of Medicine.

As founding director of the Glenn Biggs Institute for Alzheimer’s & Neurodegenerative Diseases, Dr. Seshadri will oversee, integrate, and coordinate all activities of the Biggs Institute, which will share the space of UT Health’s Barshop Institute for Longevity and Aging Studies.

Dr. Seshadri enjoys a superb reputation in both science and clinical care and is a recognized thought leader in Alzheimer’s disease having recently co-authored position papers disseminated by the National Academy of Sciences on Preventing Cognitive Decline and Dementia: A Way Forward,  and by the American Heart Association with a paper titled Defining Optimal Brain Health in Adults. She has lectured extensively, nationally and internationally, on Alzheimer’s disease, dementia and the genetics of stroke and vascular brain injury.

She is a senior investigator for the seminal Framingham Heart Study, has had peer reviewed research continuously funded by the National Institutes of Health for 10 years, and currently serves as the principal investigator on eight NIH U01 or R01 grants.


Disclosure: Dr. Seshadri has no relevant financial relationship(s), potential or perceived, with commercial or conflicts of interest to disclose.